D-Y. Oh

1.2k citations

60 papers · 745 · h-index 14

Impact in

Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research

Papers in

Oncology 48
- Colorectal Cancer Treatments and Studies 14
- HER2/EGFR in Cancer Research 9
- Pancreatic and Hepatic Oncology Research 8
- Cancer Immunotherapy and Biomarkers 7
Pulmonary and Respiratory Medicine 31
- Gastric Cancer Management and Outcomes 23

Co-authors: S-A Im (3 shared papers)Tae‐Yop Kim (5 shared papers)Kyung-Woo Lee (8 shared papers)Y-J. Bang (4 shared papers)S.R. Park (1 shared paper)Seung Woo Han (2 shared papers)Hong Song (1 shared paper)Mina Kim (1 shared paper)
Journals: Annals of Oncology (50 papers)British Journal of Cancer (4 papers)Journal of Molecular Endocrinology (1 paper)ESMO Open (1 paper)Cancer Research (1 paper)
Partner nations: South Korea United States Spain

In The Last Decade

D-Y. Oh

53 papers receiving 741 citations

Peers

Countries citing papers authored by D-Y. Oh

Since Specialization

Citations

This map shows the geographic impact of D-Y. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D-Y. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D-Y. Oh more than expected).

Fields of papers citing papers by D-Y. Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D-Y. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D-Y. Oh. The network helps show where D-Y. Oh may publish in the future.

Co-authors

The 25 scholars most cited alongside D-Y. Oh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D-Y. Oh Line = papers co-authored together D-Y. Oh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer British Journal of Cancer ·Seung Woo Han, D-Y. Oh, S-A Im, S.R. Park, Kyung-Woo Lee, Hong Song, N.S. Lee, K. H. Lee, Ik Soo Choi, M. H. Lee, Mina Kim, W H Kim, Y-J. Bang, Tae‐Yop Kim	2009	121
2	High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer British Journal of Cancer ·Dae‐Wi Kim, Hanbo Min, Kelvin H. Lee, Yoon Jun Kim, D-Y. Oh, Yoon Kyung Jeon, Seng Hua Lee, S-A Im, Doo Hyun Chung, Y T Kim, Tae‐Yop Kim, Y-J. Bang, Sook Whan Sung, Jee Hyun Kim, Dae Seog Heo	2008	83
3	LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study Annals of Oncology ·Narikazu Boku, M.-H. Ryu, D-Y. Oh, Sang Cheul Oh, Hyun Cheol Chung, Kyung-Woo Lee, Takeshi Omori, Kohei Shitara, S. Sakuramoto, Ick‐Joong Chung, Kensei Yamaguchi, Katsuhiko Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jin‐Shing Chen, L-Y. Bai, L-T. Chen, Y-K. Kang	2020	80
4	LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study Annals of Oncology ·Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sofia Oliveira, Moïshe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero	2023	46
5	Molecular cloning, pharmacological characterization, and histochemical distribution of frog vasotocin and mesotocin receptors Journal of Molecular Endocrinology ·Sujata Acharjee, J.-C. Do-Rego, D-Y. Oh, JS Moon, Ryun S. Ahn, K. Lee, DG Bai, Hubert Vaudry, HB Kwon, J Y Seong	2004	44
6	The beneficial effect of palliative resection in metastatic colorectal cancer British Journal of Cancer ·Jung‐Hyun Park, Tae‐Yop Kim, KH Lee, S-W Han, D-Y. Oh, S-A Im, Gyeong Hoon Kang, Eui Kyu Chie, S W Ha, S-Y Jeong, K J Park, JG Park	2013	41
7	Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy British Journal of Cancer ·Lee Dw, Sang-Woong Han, H-J. Lee, Rhee Yy, Bae Jm, N-Y Cho, Kihwang Lee, Kim Ty, D-Y. Oh, Im Sa, Bang Yj, S-Y. Jeong, Ki‐Jong Park, JG Park, Gyeong Hoon Kang, (unknown)	2013	39
8	VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study Annals of Oncology ·Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber, Yibing Bai, M.H. Ryu, J. Lee, F. Rivera, G.V. Alves, Marcelo Garrido, K-K. Shiu, M. González Fernández, J. Li, M. Lowery, T. Çil, F.J.S.M. Cruz, S. Qin, L. Yin, S. Bordia, P. Bhagia, D-Y. Oh	2023	33
9	1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer Annals of Oncology ·Maria E. Cabanillas, Alexander Drilon, Anna F. Farago, Marcia S. Brose, Ray McDermott, Davendra Sohal, D-Y. Oh, M. Almubarak, Jessica R. Bauman, Edward Chu, Shivaani Kummar, Serge Leyvraz, K. Park, John A. Reeves, L. Dima, Patricia Maeda, Leonardo O. Rodrigues, Nicoletta Brega, David S. Hong, Steven G. Waguespack	2020	27
10	LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial Annals of Oncology ·A. Hollebecque, Mitesh J. Borad, Lipika Goyal, A. Schram, J.O. Park, P.A. Cassier, Suneel D. Kamath, D.T. Wai Meng, E. Dotan, R. Kim, V. Sahai, D-Y. Oh, C-Y. Liao, M. Millward, D. Roda Perez, C. Ferté, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley	2022	22
11	209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors Annals of Oncology ·Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Anthony W.H. Chan, Erika Hamilton, Sherene Loi, D-Y. Oh, Leisha A. Emens, Amita Patnaik, J.E. Kim, Y.H. Park, Valerie Odegard, Sue Hamke, Geundoo Jang, Céline Jacquemont, Naomi Hunder, Sarina A. Piha‐Paul	2021	20
12	654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study Annals of Oncology ·Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian C. Anderson, Giuseppe Curigliano, Maria J. de Miguel, Mamta Kalra, D-Y. Oh, J.O. Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Aaron Smith, K. K. Machado, C. Saura Manich	2023	19
13	56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) Annals of Oncology ·D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Watras, G. Cohen, J.W. Valle	2022	19
14	1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A Annals of Oncology ·Daniel V.T. Catenacci, H. Park, Byoung Yong Shim, S.T. Kim, D-Y. Oh, Alexander I. Spira, Susanna V. Ulahannan, Eric J. Avery, Patrick M. Boland, Joseph Chao, Hyun Cheol Chung, F. Gardner, S.J. Klempner, Kyung-Woo Lee, Sang Cheul Oh, Julio A. Peguero, Mohamad Bassam Sonbol, Jichao Sun, Minori Koshiji Rosales, Y-K. Kang	2021	13
15	68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC) Annals of Oncology ·J.W. Valle, S. Qin, L. Antonuzzo, D. Tougeron, CK Lee, B.J. Tan, M. Ikeda, V. Guthrie, P. McCoon, Y.S. Lee, N. Rokutanda, M. Żotkiewicz, G. Cohen, D-Y. Oh	2022	12
16	1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) Annals of Oncology ·Y. Y. Janjigian, Hanneke W.M. van Laarhoven, Sun Young Rha, V S Kozlov, D-Y. Oh, A. Gravina, L. Rapatoni, H. Shoji, R.D. Hofheinz, L-T. Chen, Hugo Ford, Maxime Chénard-Poirier, Saeed Raoufmoghaddam, C. Lloyd, Chi Zhang, C. Mateo, Jae Man Lee	2024	11
17	1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC) Annals of Oncology ·Mustapha Tehfé, J. Lee, Sun Young Rha, Yoshiaki Nakamura, Josep Tabernero, Kohei Shitara, D-Y. Oh, Jennifer R. Eads, J. Marshall, Zev A. Wainberg, Kyung-Woo Lee, Y-K. Kang, C-Y. Liao, Sung Yong Oh, Kun‐Huei Yeh, Donald Richards, Michelle Ubowski, K. Zhao, S. Bhaumik, John H. Strickler	2023	8
18	397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305 Annals of Oncology ·Markus Moehler, D-Y. Oh, Kazuyoshi Kato, Josep Tabernero, Marcia Cruz‐Correa, Lucjan Wyrwicz, Roberto Pazo-Cid, A. Cubillo, Ludovic Evesque, Lorenzo Fornaro, Eden Dotan, Carys Morgan, L. Li, Yaling Xu, Tao Sheng, Shu‐Hua Yang, Hong Hu, R-H. Xu	2024	7
19	606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors Annals of Oncology ·Funda Meric‐Bernstam, Yoichi Naito, Stéphanie Gaillard, T. Shimoi, Vincent Chung, Andrew A. Davis, Theresa A. Proia, Amal Ayyoub, Manjusha Kulkarni, Sameer Upadhyay, Neil R. Miller, Nadia Luheshi, Andreea Varga, D-Y. Oh, Linda Mileshkin	2024	7
20	1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study Annals of Oncology ·Kyung-Woo Lee, L-Y. Bai, Minkyu Jung, Jieer Ying, Y-H Im, D-Y. Oh, Y. Choi, Sang Cheul Oh, Yee Chao, Zhou Ping, Y. Bao, Y-K. Kang	2023	6

About D-Y. Oh

D-Y. Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 60 papers that have together received 745 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (23 papers), Colorectal Cancer Treatments and Studies (14 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), HER2/EGFR in Cancer Research (9 papers), Pancreatic and Hepatic Oncology Research (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Gastrointestinal Tumor Research and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Gastroenterology (116 citations), Oncology (496 citations), Pulmonary and Respiratory Medicine (388 citations), Surgery (237 citations) and Immunology (98 citations). D-Y. Oh has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include S-A Im, Tae‐Yop Kim, Kyung-Woo Lee, Y-J. Bang, S.R. Park, Seung Woo Han, Hong Song, Mina Kim, W H Kim and Takeshi Omori. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, Journal of Molecular Endocrinology, ESMO Open and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

D-Y. Oh

Impact in

Papers in i

In The Last Decade

D-Y. Oh

Peers

Countries citing papers authored by D-Y. Oh

Fields of papers citing papers by D-Y. Oh

All Works

About D-Y. Oh

Explore authors with similar magnitude of impact

Papers in